Previous Close | 0.2650 |
Open | 0.2750 |
Bid | 0.2550 x 0 |
Ask | 0.2750 x 0 |
Day's Range | 0.2550 - 0.2750 |
52 Week Range | 0.1500 - 1.2200 |
Volume | |
Avg. Volume | 118,462 |
Market Cap | 39.367M |
Beta (5Y Monthly) | 2.75 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3450 |
Earnings Date | Nov 28, 2022 - Dec 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.50 |
PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today provided a corporate update, regarding progress against the efficiency initiatives it began to implement in mid-2021, which are designed to accelerate the Company's path to profitability. The Company also announced its intention to amend exist
PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has received its first commercial purchase order for API from Ease Labs Pharma ("Ease Labs"), a multinational, GMP certified pharmaceutical company headquartered in Brazil. PharmaCielo and Ease Labs have signed an ongoing sal
PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has made an initial shipment of CBD Isolate to a pharmaceutical company in Morocco, to facilitate pre-commercial testing. The customer is developing a portfolio of cannabinoid medicines, both non-psychoactive, and ps